利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

153 条记录 (耗时 0.047 秒)

    ANTIBODY-BINDING PEPTIDE
    61.
    发明申请
    ANTIBODY-BINDING PEPTIDE 有权
    抗体结合肽

    公开(公告)号：US20150353608A1

    公开(公告)日：2015-12-10

    申请号：US14763589

    申请日：2013-12-25

    申请人： National Institute of Advanced Industrial Science and Technology

    发明人： Hideki WATANABE ,  Shinya HONDA

    IPC分类号： C07K14/00 ,  C07K7/06 ,  C07K7/08

    CPC分类号： C07K14/001 ,  C07K7/06 ,  C07K7/08 ,  C07K16/4208 ,  G01N33/6854

    摘要： The invention relates to polypeptides consisting of amino acid sequences represented by the following formulas 1 to 4, which have binding activity to an Fc region of immunoglobulin G and can be favorably used in detecting, purifying, immobilizing or removing an antibody, immunoglobulin G or a protein containing an Fc region of immunoglobulin G, (SEQ ID NO: 1) Y-D-P-x-T-G-T-W-R-S-x-[IL] (1) (SEQ ID NO: 10) R-[QRS]-x-x-[GS]-Y-D-P-R-T-G-T-W-R-S-S-I-A-Y-G-G (2) (SEQ ID NO: 20) G-V-V-R-Q-W-S-G-x-x-x-x-x-x-x-x-R-S-S-I-A-Y-G-G (3) (SEQ ID NO: 23) D-A-A-W-H-L-G-E-L-V-W-A-T-Y-Y-D-P-E-T-G-T-W-x-P-D- W-x-x-M (4) where x represents any amino acid residue; and amino acid residues within the square brackets indicate that any one of the amino acid residues is selected.

    摘要翻译： 本发明涉及由下式1〜4表示的氨基酸序列组成的多肽，其具有与免疫球蛋白G的Fc区的结合活性，可有利地用于检测，纯化，固定或除去抗体，免疫球蛋白G或 含有免疫球蛋白G的Fc区的蛋白质（SEQ ID NO：1）YDPxTGTWRSx- [IL]（1）（SEQ ID NO：10）R- [QRS] -xx- [GS] -YDPRTGTWRSSIAYGG（2）（SEQ ID NO： NO：20）GVVRQWSGxxxxxxxxRSSIA-YGG（3）（SEQ ID NO：23）DAAWHLGELVWATYYDPETGT-WxPD-WxxM（4）其中x表示任何氨基酸残基; 方括号内的氨基酸残基表示选择任何一个氨基酸残基。

    IP-10 ANTIBODY DOSAGE ESCALATION REGIMENS
    65.
    发明申请
    IP-10 ANTIBODY DOSAGE ESCALATION REGIMENS 有权
    IP-10抗体剂量自动化程序

    公开(公告)号：US20140127229A1

    公开(公告)日：2014-05-08

    申请号：US14055238

    申请日：2013-10-16

    申请人： BRISTOL-MYERS SQUIBB COMPANY

    发明人： Allison Y. Luo ,  Wendy L. Trigona ,  Jinshan Shen ,  Li-An Xu ,  Yan Zhang ,  Bruce Stouffer ,  Haibin Chen ,  Haichun Huang ,  Xiaolu Tao ,  Catherine Brockus

    IPC分类号： G01N33/68

    CPC分类号： G01N33/686 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/24 ,  C07K16/4208 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2317/90

    摘要： In certain embodiments, the present invention provides a method of treating an IP-10-related disease in a subject, comprising: (a) administering to the subject a predetermined dosage of an anti-IP-10 antibody; (b) detecting the level of the anti-IP-10 antibody in a sample of the subject; and (c) if the level of the anti-IP-10 antibody from step (b) is below a threshold exposure level, increasing the dosage of the anti-IP-10 antibody in the subject such that the IP-10 related disease in the subject is treated. In certain embodiments, the present invention provides an isolated monoclonal anti-idiotypic antibody, or an antigen binding portion thereof, which binds to the anti-IP-10 antibody MDX-1100.

    摘要翻译： 在某些实施方案中，本发明提供了治疗受试者中IP-10相关疾病的方法，包括：（a）向受试者施用预定剂量的抗-IP-10抗体; （b）检测受试者样品中抗-IP-10抗体的水平; 和（c）如果来自步骤（b）的抗-IP-10抗体的水平低于临界暴露水平，则增加受试者中抗-IP-10抗体的剂量使得IP-10相关疾病在 该主题得到对待。 在某些实施方案中，本发明提供了与抗-IP-10抗体MDX-1100结合的分离的单克隆抗独特型抗体或其抗原结合部分。

    Genus-wide chlamydial peptide vaccine antigens
    66.
    发明授权
    Genus-wide chlamydial peptide vaccine antigens 有权
    广谱衣原体肽疫苗抗原

    公开(公告)号：US08637040B2

    公开(公告)日：2014-01-28

    申请号：US13120071

    申请日：2009-09-21

    申请人： Judith Whittum-Hudson ,  Alan P. Hudson

    发明人： Judith Whittum-Hudson ,  Alan P. Hudson

    IPC分类号： A61K39/118

    CPC分类号： C07K16/125 ,  A61K39/118 ,  C07K7/06 ,  C07K7/08 ,  C07K16/4208 ,  G01N33/56927 ,  G01N2469/20

    摘要： Peptides generated from a random library that are bound by a monoclonal antibody to Chlamydial glycolipid exoantigen (GLXA) and thus mimic this antigen are disclosed. Peptides that correspond to antigen-binding regions of an anti-idiotypic antibody (mAb2) specific for anti-GLXA antibody (Ab1) which act as molecular mimics of GLXA are also disclosed used as immunogens to induce broadly reactive genus-specific anti-chlamydial antibodies. These peptides and immunogenic DNA encoding the mAb2-like peptides, microparticle or nanoparticle formulations and other formulations of these peptides are disclosed as are methods for immunizing subjects to obtain genus-specific anti-chlamydial antibodies and to treat or prevent Chlamydia-associated or induced rheumatoid arthritis.

    摘要翻译： 公开了从由衣原体糖脂外源抗原（GLXA）的单克隆抗体结合并因此模拟该抗原的随机文库产生的肽。 对应于作为GLXA分子模拟物的抗GLXA抗体（Ab1）特异的抗独特型抗体（mAb2）的抗原结合区的肽也被公开用作免疫原，以诱导广泛活性的特异性抗衣原体抗体 。 公开了编码mAb2样肽，微粒或纳米颗粒制剂和这些肽的其它制剂的这些肽和免疫原性DNA，用于免疫受试者以获得属特异性抗衣原体抗体并治疗或预防衣原体相关或诱导的类风湿病的方法 关节炎。

    Compositions and methods for treatment of cervical cancer
    67.
    发明授权
    Compositions and methods for treatment of cervical cancer 有权
    用于治疗子宫颈癌的组合物和方法

    公开(公告)号：US08114414B2

    公开(公告)日：2012-02-14

    申请号：US11715497

    申请日：2007-03-08

    申请人： Yvonne Paterson ,  John Rothman

    发明人： Yvonne Paterson ,  John Rothman

    IPC分类号： A61K39/02

    CPC分类号： A61K39/0011 ,  A61K39/00 ,  A61K2039/505 ,  A61K2039/523 ,  A61K2039/53 ,  C07K14/195 ,  C07K14/70503 ,  C07K16/00 ,  C07K16/1285 ,  C07K16/4208 ,  C07K2317/622 ,  C07K2319/00

    摘要： The present invention provides methods of treating, protecting against, and inducing an immune response against cervical cancer, comprising the step of administering to a subject a recombinant Listeria strain, comprising a fusion peptide that comprises an LLO fragment and an E7 and/or E6 antigen. The present invention also provides methods for inducing an anti-E7 response in a human subject and treating HPV-mediated diseases, disorders, and symptoms comprising administration of the recombinant Listeria strain.

    摘要翻译： 本发明提供了治疗，保护和诱导针对子宫颈癌的免疫应答的方法，包括向受试者施用包含融合肽的重组利斯特氏菌菌株的步骤，所述融合肽包含LLO片段和E7和/或E6抗原 。 本发明还提供在人受试者中诱导抗E7应答并治疗HPV介导的疾病，病症和症状的方法，包括施用重组利斯特氏菌属菌株。

    USES OF MONOCLONAL ANTIBODY 8H9
    68.
    发明申请
    USES OF MONOCLONAL ANTIBODY 8H9 有权
    单克隆抗体8H9的用途

    公开(公告)号：US20100284920A1

    公开(公告)日：2010-11-11

    申请号：US12721798

    申请日：2010-03-11

    申请人： Nai-Kong V. CHEUNG

    发明人： Nai-Kong V. CHEUNG

    IPC分类号： A61K49/00 ,  A61K39/395 ,  C07K16/00 ,  C07K14/00 ,  C12N15/63 ,  C12N5/10 ,  C12P21/06

    CPC分类号： C07K16/28 ,  A01K2217/05 ,  A61K47/6865 ,  A61K47/6873 ,  A61K49/0004 ,  A61K49/0006 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/18 ,  C07K16/30 ,  C07K16/3053 ,  C07K16/4208 ,  C07K16/4266 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2319/00

    摘要： This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides different uses of the monoclonal antibody 8H9 or its derivative.

    摘要翻译： 本发明提供了包含有效量的单克隆抗体8H9或其衍生物和合适的载体的组合物。 本发明提供了包含有效量的单克隆抗体8H9或其衍生物和药学上可接受的载体的药物组合物。 本发明还提供除单克隆抗体8H9之外的抗体，其包含能够与单克隆抗体8H9结合相同抗原的单克隆抗体8H9或其衍生物的互补决定区。 本发明提供能够竞争性抑制单克隆抗体8H9结合的物质。 本发明还提供单克隆抗体8H9或其衍生物的分离的scFv。 本发明还提供了8H9抗原。 本发明还提供了单克隆抗体8H9或其衍生物的不同用途。

    CHAIN REACTION CREATING OLIGOMERS FROM REPEAT UNITS OF BINDING MOLECULES
    69.
    发明申请
    CHAIN REACTION CREATING OLIGOMERS FROM REPEAT UNITS OF BINDING MOLECULES 审中-公开
    链条反应创建复合分子重复单元的寡聚体

    公开(公告)号：US20100233167A1

    公开(公告)日：2010-09-16

    申请号：US12597948

    申请日：2008-05-09

    申请人： Ramesh Bhatt ,  Lawrence Horowitz

    发明人： Ramesh Bhatt ,  Lawrence Horowitz

    IPC分类号： A61K39/395 ,  C07K16/46 ,  A61P35/00

    CPC分类号： C07K16/4208 ,  C07K16/00 ,  C07K16/283 ,  C07K16/32 ,  C07K16/42 ,  C07K2317/31 ,  C07K2317/32

    摘要： The present invention concerns a chain reaction of cross-linking antibodies or other binding molecules prior or subsequent to binding to a target, such as a target antigen. The invention further concerns oligomers comprising repeat units of binding molecules, such as antibodies, optionally bound to a target, such as a target antigen. The invention also relates to antibodies and other binding molecules with multiple specificities useful in the methods of the invention, as well as various uses of the oligomers and individual binding molecules present in the oligomers.

    摘要翻译： 本发明涉及在与靶标（例如靶抗原）结合之前或之后的交联抗体或其它结合分子的连锁反应。 本发明还涉及包含结合分子的重复单元的寡聚体，例如任选地与靶标结合的抗体，例如靶抗原。 本发明还涉及具有多种特异性的抗体和其它结合分子，其可用于本发明的方法，以及低聚物中存在的寡聚体和单独结合分子的各种用途。

    Variants of humanized anti-carcinoma MAb CC49
    70.
    发明授权
    Variants of humanized anti-carcinoma MAb CC49 有权
    人源化抗癌MAb CC49的变体

    公开(公告)号：US07763719B2

    公开(公告)日：2010-07-27

    申请号：US11776437

    申请日：2007-07-11

    申请人： Syed V S. Kashmiri ,  Eduardo A. Padlan ,  Jeffrey Schlom

    发明人： Syed V S. Kashmiri ,  Eduardo A. Padlan ,  Jeffrey Schlom

    IPC分类号： C07H21/04

    CPC分类号： A61K49/0002 ,  A61K38/00 ,  A61K51/1045 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3046 ,  C07K16/4208 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2799/026 ,  G01N33/5743

    摘要： The invention is directed towards mouse-human chimeric variants of CC49 monoclonal antibodies with minimal murine content. A first aspect of the invention provides CDR variants of humanized monoclonal antibody (HuCC49) in which less than all six (three heavy chain and three light chain) Complementarity Determining Regions (CDRs) of CC49 are present. A second aspect of the invention provides SDR variants of humanized monoclonal antibody (HuCC49) in which only Specificity Determining Regions (SDRs) of at least one CDR from CC49 are present. The invention is also directed towards biotechnological methods of making the variants and therapeutic methods of using the variants.

    摘要翻译： 本发明针对具有最小鼠含量的CC49单克隆抗体的小鼠 - 人嵌合变体。 本发明的第一方面提供了存在CC49的全部六（三个重链和三个轻链）互补决定区（CDR）的人源化单克隆抗体（HuCC49）的CDR变体。 本发明的第二方面提供了仅存在来自CC49的至少一个CDR的特异性确定区（SDR）的人源化单克隆抗体（HuCC49）的SDR变体。 本发明还涉及制备使用变体的变体和治疗方法的生物技术方法。